Cargando…

p53 destabilizing protein skews asymmetric division and enhances NOTCH activation to direct self-renewal of TICs

Tumor-initiating stem-like cells (TICs) are defective in maintaining asymmetric cell division and responsible for tumor recurrence. Cell-fate-determinant molecule NUMB-interacting protein (TBC1D15) is overexpressed and contributes to p53 degradation in TICs. Here we identify TBC1D15-mediated oncogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hye Yeon, Siddique, Hifzur R., Zheng, Mengmei, Kou, Yi, Yeh, Da-Wei, Machida, Tatsuya, Chen, Chia-Lin, Uthaya Kumar, Dinesh Babu, Punj, Vasu, Winer, Peleg, Pita, Alejandro, Sher, Linda, Tahara, Stanley M., Ray, Ratna B., Liang, Chengyu, Chen, Lin, Tsukamoto, Hidekazu, Machida, Keigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299990/
https://www.ncbi.nlm.nih.gov/pubmed/32555153
http://dx.doi.org/10.1038/s41467-020-16616-8
Descripción
Sumario:Tumor-initiating stem-like cells (TICs) are defective in maintaining asymmetric cell division and responsible for tumor recurrence. Cell-fate-determinant molecule NUMB-interacting protein (TBC1D15) is overexpressed and contributes to p53 degradation in TICs. Here we identify TBC1D15-mediated oncogenic mechanisms and tested the tumorigenic roles of TBC1D15 in vivo. We examined hepatocellular carcinoma (HCC) development in alcohol Western diet-fed hepatitis C virus NS5A Tg mice with hepatocyte-specific TBC1D15 deficiency or expression of non-phosphorylatable NUMB mutations. Liver-specific TBC1D15 deficiency or non-p-NUMB expression reduced TIC numbers and HCC development. TBC1D15–NuMA1 association impaired asymmetric division machinery by hijacking NuMA from LGN binding, thereby favoring TIC self-renewal. TBC1D15–NOTCH1 interaction activated and stabilized NOTCH1 which upregulated transcription of NANOG essential for TIC expansion. TBC1D15 activated three novel oncogenic pathways to promote self-renewal, p53 loss, and Nanog transcription in TICs. Thus, this central regulator could serve as a potential therapeutic target for treatment of HCC.